Access to Advanced Health Institute (AAHI)
30
0
0
24
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
3.3%
1 terminated/withdrawn out of 30 trials
96.0%
+9.5% vs industry average
0%
0 trials in Phase 3/4
25%
6 of 24 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (30)
Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy
Role: collaborator
Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV
Role: collaborator
Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults
Role: collaborator
A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum
Role: collaborator
A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted
Role: collaborator
Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults
Role: collaborator
Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults
Role: lead
A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate
Role: collaborator
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Role: collaborator
Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
Role: collaborator
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
Role: collaborator
Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children
Role: collaborator
Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers
Role: collaborator
Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers
Role: lead
Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion
Role: lead
Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers
Role: lead
Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions
Role: collaborator
Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers
Role: lead
Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers
Role: lead
Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India
Role: lead